PL3675854T3 - Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3 - Google Patents

Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Info

Publication number
PL3675854T3
PL3675854T3 PL18769510.1T PL18769510T PL3675854T3 PL 3675854 T3 PL3675854 T3 PL 3675854T3 PL 18769510 T PL18769510 T PL 18769510T PL 3675854 T3 PL3675854 T3 PL 3675854T3
Authority
PL
Poland
Prior art keywords
glomerulopathy
piperidinyl
treatment
indole derivatives
indole
Prior art date
Application number
PL18769510.1T
Other languages
English (en)
Inventor
Jörg EDER
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3675854T3 publication Critical patent/PL3675854T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18769510.1T 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3 PL3675854T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31
PCT/IB2018/056618 WO2019043609A1 (en) 2017-08-31 2018-08-30 NEW USES OF PIPERIDINYL-INDOLE DERIVATIVES

Publications (1)

Publication Number Publication Date
PL3675854T3 true PL3675854T3 (pl) 2025-05-19

Family

ID=59745840

Family Applications (2)

Application Number Title Priority Date Filing Date
PL24170648.0T PL4393545T3 (pl) 2017-08-31 2018-08-30 Nowe zastosowania pochodnych piperydynylo-indolowych
PL18769510.1T PL3675854T3 (pl) 2017-08-31 2018-08-30 Pochodne piperydynyloindolu do zastosowania w leczeniu glomerulopatii c3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL24170648.0T PL4393545T3 (pl) 2017-08-31 2018-08-30 Nowe zastosowania pochodnych piperydynylo-indolowych

Country Status (22)

Country Link
US (3) US11723901B2 (pl)
EP (3) EP4393545B1 (pl)
JP (3) JP6754919B1 (pl)
KR (3) KR102682887B1 (pl)
CN (5) CN117398384A (pl)
AU (1) AU2018326768B2 (pl)
BR (1) BR112020003737A2 (pl)
CA (1) CA3073346A1 (pl)
CL (1) CL2020000483A1 (pl)
DK (2) DK3675854T3 (pl)
ES (2) ES3022885T3 (pl)
FI (2) FI3675854T3 (pl)
HR (2) HRP20250386T1 (pl)
HU (1) HUE071118T2 (pl)
IL (1) IL272888B2 (pl)
LT (2) LT4393545T (pl)
MX (3) MX2020002185A (pl)
PL (2) PL4393545T3 (pl)
PT (2) PT4393545T (pl)
RS (2) RS66635B1 (pl)
SI (2) SI4393545T1 (pl)
WO (1) WO2019043609A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
WO2021125313A1 (ja) * 2019-12-19 2021-06-24 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
KR20250048392A (ko) 2020-05-18 2025-04-08 노파르티스 아게 Lnp023의 결정질 형태
US20230286947A1 (en) * 2020-08-07 2023-09-14 Shanghai Meiyue Biotech Development Co. Ltd Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN119798256A (zh) * 2020-12-30 2025-04-11 江苏恒瑞医药股份有限公司 含氮桥杂环化合物、其制备方法及其在医药上的应用
JP7641388B2 (ja) * 2020-12-30 2025-03-06 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド 一連のピペリジン置換安息香酸系化合物及びその使用
JP2024517234A (ja) * 2021-05-07 2024-04-19 ノバルティス アーゲー 非典型溶血性尿毒症症候群の処置のためのイプタコパン
CA3229360A1 (en) * 2021-08-18 2023-02-23 Chen Zhang Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
EP4423076A4 (en) * 2021-10-27 2026-01-07 Hansoh Bio Llc PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES
CR20240300A (es) * 2022-01-24 2024-08-23 Novartis Ag Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
EP4471021A4 (en) * 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN119343347A (zh) * 2022-06-10 2025-01-21 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
US20250382287A1 (en) 2022-06-30 2025-12-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same
CN117327070A (zh) * 2022-06-30 2024-01-02 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的晶型及其制备方法
JP2025530222A (ja) * 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
EP4617266A1 (en) 2022-11-11 2025-09-17 Shanghai Yisheng Biopharmaceutical company Limited Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
TWI896250B (zh) * 2023-07-26 2025-09-01 大陸商上海美悦生物科技發展有限公司 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
WO2026086939A1 (zh) * 2024-10-25 2026-04-30 上海美悦生物科技发展有限公司 杂环化合物在制备预防或治疗IgA肾病的药物中的用途
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
CN105229003B (zh) * 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
SG11201805695SA (en) * 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
KR20250048392A (ko) 2020-05-18 2025-04-08 노파르티스 아게 Lnp023의 결정질 형태
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors

Also Published As

Publication number Publication date
US20220152011A1 (en) 2022-05-19
EP4647121A2 (en) 2025-11-12
FI3675854T3 (fi) 2025-04-07
PT3675854T (pt) 2025-04-04
EP3675854B1 (en) 2025-01-22
WO2019043609A1 (en) 2019-03-07
HRP20250386T1 (hr) 2025-05-23
JP6754919B1 (ja) 2020-09-16
JP2020529466A (ja) 2020-10-08
LT3675854T (lt) 2025-04-25
RU2020111788A3 (pl) 2021-12-28
EP4393545A3 (en) 2024-09-25
US12285422B2 (en) 2025-04-29
KR102682887B1 (ko) 2024-07-08
RS67530B1 (sr) 2026-01-30
KR20200047540A (ko) 2020-05-07
CN111032042A (zh) 2020-04-17
EP4647121A3 (en) 2026-02-18
JP6929425B2 (ja) 2021-09-01
ES3022885T3 (en) 2025-05-29
EP4393545A2 (en) 2024-07-03
RS66635B1 (sr) 2025-04-30
DK3675854T3 (da) 2025-04-07
DK4393545T3 (da) 2026-01-12
AU2018326768A1 (en) 2020-02-06
IL272888A (en) 2020-04-30
SI4393545T1 (sl) 2026-02-27
KR20240111007A (ko) 2024-07-16
US20200338059A1 (en) 2020-10-29
MX2023010750A (es) 2023-09-20
ES3058507T3 (en) 2026-03-11
MX2023010751A (es) 2023-09-20
BR112020003737A2 (pt) 2020-09-01
PL4393545T3 (pl) 2026-03-16
IL272888B1 (en) 2023-09-01
KR102497487B1 (ko) 2023-02-08
EP3675854A1 (en) 2020-07-08
CN117338782A (zh) 2024-01-05
CN117338781A (zh) 2024-01-05
FI4393545T3 (fi) 2026-01-14
CN117398384A (zh) 2024-01-16
CA3073346A1 (en) 2019-03-07
US20250195493A1 (en) 2025-06-19
PT4393545T (pt) 2025-12-23
CL2020000483A1 (es) 2020-09-04
HRP20251596T1 (hr) 2026-01-30
SI3675854T1 (sl) 2025-05-30
LT4393545T (lt) 2026-01-12
RU2020111788A (ru) 2021-09-30
IL272888B2 (en) 2024-01-01
AU2018326768B2 (en) 2021-07-29
EP4393545B1 (en) 2025-10-08
CN117338783A (zh) 2024-01-05
HUE071118T2 (hu) 2025-08-28
KR20230024432A (ko) 2023-02-20
JP2020193222A (ja) 2020-12-03
US11723901B2 (en) 2023-08-15
JP7297016B2 (ja) 2023-06-23
MX2020002185A (es) 2020-07-14
JP2021181471A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
LT3675854T (lt) Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
GB2538923B (en) A therapeutic agent for use in the treatment of infections
GB201617064D0 (en) Compounds and their therapeutic use
IL246855A0 (en) Materials for use in the treatment of retinitis
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
PT3049085T (pt) Inibidores de sgk1 no tratamento da síndrome do qt longo
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
PL3370727T3 (pl) Nieulegające biokonwersji c3-podstawione pochodne pregnenolonu do zastosowania w leczeniu zaburzeń związanych z nadużywaniem substancji
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases